Abstract
Primary (neoadjuvant, preoperative) chemotherapy for surgically curative breast cancer is a novel treatment approach. The sequentially combined strategy derives from prior experience achieved with locally advanced (stage III) disease in which primary chemotherapy including a regimen containing doxorubicin (Adriamycin) was delivered to achieve prompt tumor shrinkage and thus facilitate subsequent mastectomy and/or irradiation [1–4]. In recent years primary chemotherapy has been tested in resectable breast cancer with multifold clinical aims: (a) to increase the frequency of breast- saving procedures in tumors whose size would require mastectomy, (b) to decrease the frequency of local recurrence, and (c) to further improve relapse-free and total survival rates over those recently achieved with systemic adjuvant treatments [2, 5, 6] (the latter of these is reprinted in part in this volume). This paper summarizes and updates the clinical results of the prospective trial started in 1988 at the Milan Cancer Institute [7].
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonadonna G (1989) Conceptual and practical advances in the management of breast cancer. Karnofsky Memorial Lecture. J Clin Oncol 7:1380–1397
Bonadonna G (1992) Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52:2127–2137
Valagussa P, Zambetti M, Bonadonna G et al. (1990) Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res Treat 15:137–147
Hortobagyi GN (1990) Comprehensive management of locally advanced breast cancer. Cancer 66:1387–1391
Bonadonna G, Valagussa P, Brambilla C et al. (1991) Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy. Semin Oncol 18:515–524
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339:1–15, 71–85
Bonadonna G, Veronesi U, Brambilla C et al. (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539–1545
Forrest APM, Levack PA, Chetty U et al. (1986) A human tumour model. Lancet 2:840–842
Mansi JL, Smith IE, Walsh G et al. (1989) Primary medical therapy for operable breast cancer. Eur J Cancer Clin Oncol 25:1623–1627
Jacquillat C, Weil M, Baillet F et al. (1990) Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66:119–129
Banzet P, Holland JF, Khayat D, Weil M (eds) (1991) Neoadjuvant chemotherapy. Springer, Berlin Heidelberg New York
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Bonadonna, G. et al. (1993). Primary Chemotherapy for Resectable Breast Cancer. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Breast Cancer IV. Recent Results in Cancer Research, vol 127. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84745-5_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-84745-5_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-84747-9
Online ISBN: 978-3-642-84745-5
eBook Packages: Springer Book Archive